As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.
11 Analysts have issued a Biodesix Inc forecast:
11 Analysts have issued a Biodesix Inc forecast:
Jun '25 |
+/-
%
|
||
Revenue | 77 77 |
26%
26%
|
|
Gross Profit | 60 60 |
28%
28%
|
|
EBITDA | -28 -28 |
2%
2%
|
EBIT (Operating Income) EBIT | -34 -34 |
2%
2%
|
Net Profit | -41 -41 |
8%
8%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. It offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer; and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It is a data-driven diagnostic solutions company with proprietary AI platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. The firm offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. . The company was founded in 2005 and is headquartered in Boulder, CO.
Head office | United States |
CEO | Scott Hutton |
Employees | 273 |
Founded | 2005 |
Website | www.biodesix.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.